[HTML][HTML] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - The Lancet, 2018 - thelancet.com
Background Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
CC Parker, ND James, CD Brawley… - Lancet (London …, 2018 - folia.unifr.ch
METHODS We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and
the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly …
the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly …
[HTML][HTML] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - The Lancet, 2018 - thelancet.com
Background Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - Lancet, 2018 - discovery.ucl.ac.uk
BACKGROUND: Local treatment of the prostate might not only improve local control, but
also slow the progression of metastatic disease. We hypothesised that radiotherapy (RT) to …
also slow the progression of metastatic disease. We hypothesised that radiotherapy (RT) to …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
CC Parker, ND James, CD Brawley, NW Clarke… - 2018 - repository.icr.ac.uk
BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the
prostate would improve overall survival in men with metastatic prostate cancer, and that the …
prostate would improve overall survival in men with metastatic prostate cancer, and that the …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
CC Parker, ND James, CD Brawley, NW Clarke… - Lancet (London …, 2018 - sonar.ch
METHODS We did a randomised controlled phase 3 trial at 117 hospitals in Switzerland and
the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly …
the UK. Eligible patients had newly diagnosed metastatic prostate cancer. We randomly …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - 2018 - christie.openrepository.com
Background Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
CC Parker, ND James, CD Brawley, NW Clarke… - …, 2018 - researchonline.lshtm.ac.uk
BACKGROUND: Based on previous findings, we hypothesised that radiotherapy to the
prostate would improve overall survival in men with metastatic prostate cancer, and that the …
prostate would improve overall survival in men with metastatic prostate cancer, and that the …
[HTML][HTML] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - The Lancet, 2018 - Elsevier
Background Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - Lancet, 2018 - eprints.gla.ac.uk
Background: Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …